MEFLAM (Mefenamic acid)

MEFLAM (Mefenamic acid)


Mefenamic inhibits the cyclo-oxygenase enzyme and thus exerts its anti-inflammatory activity by inhibition of prostaglandin synthesis. Mefenamic acid has antipyretic and antipyretic and analgesic properties acting by both central and peripheral mechanisms

MEFLAM (Mefenamic acid)


As an anti-inflammatory analgesic for the symptomatic relief of rheumatoid arthritis (including juvenile chronic arthritis), osteoarthritis and pain including muscular, traumatic and dental pain, headaches of most aetiology including migraine, post-operative and post-partum pain

Primary dysmenorrhea

Menorrhagia due to dysfunctional causes and presence of an IUD when other pelvic pathology has been ruled out


Administration id by the oral route, preferably with food. The recommended regimen in acute pain for adults and children over 14 years of age is 500 mg as an initial dose followed by 250 mg every 6 hours as needed, usually not to exceed 1 week. For the treatment of primary dysmenorrhoea, the recommended dosage is 500 mg as an initial dose followed by 250 mg every 6 hours, starting with onset of bleeding and associated symptoms


Side effects

The most frequently reported adverse reactions associated with the use of mefenamic acid involve the gastrointestinal tract in controlled studies for up to eight months, the following disturbances were reported in decreasing order of frequency: diarrhea, nausea, vomiting, abdominal pain, anorexia, flatulence and constipation


Mefenamic acid is contraindicated in patients who have previously exhibited hypersensitivity to it or other NSAIDs. Mefenamic acid is contra-indicated in patients with active ulceration or chronic inflammation of either the upper or lower gastrointestinal tract. Mefenamic acid should be avoided in patients with pre-existing renal disease

Share this

Leave a Comment

Your email address will not be published. Required fields are marked *

you're currently offline